AI Article Synopsis
- Recent outbreaks of Ebola virus disease (EVD) in West Africa and the DRC have emphasized the urgent need for quick diagnostic tests.
- The study evaluated the QuickNavi-Ebola immunochromatography kit by testing 928 blood samples from suspected EVD cases during the 2018 DRC outbreaks alongside the WHO-approved GeneXpert.
- QuickNavi-Ebola showed a sensitivity of 85% and a specificity of 99.8%, demonstrating its effectiveness for on-site EVD diagnosis.
Article Abstract
The recent large outbreaks of Ebola virus disease (EVD) in West Africa and the Democratic Republic of the Congo (DRC) have highlighted the need for rapid diagnostic tests to control this disease. In this study, we clinically evaluated a previously developed immunochromatography-based kit, QuickNavi-Ebola. During the 2018 outbreaks in DRC, 928 blood samples from EVD-suspected cases were tested with QuickNavi-Ebola and the WHO-approved GeneXpert. The sensitivity and specificity of QuickNavi-Ebola, estimated by comparing it to GeneXpert-confirmed cases, were 85% (68/80) and 99.8% (846/848), respectively. These results indicate the practical reliability of QuickNavi-Ebola for point-of-care diagnosis of EVD.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6669708 | PMC |
| http://dx.doi.org/10.3390/v11070589 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!